Press release
Immunoglobulin A (IgA) Nephropathy to Witness an Exponential Growth due to Positive Clinical Results in the Coming Years | Key Players are Mallinckrodt Pharmaceuticals, Pharmalink AB, Anthera Pharmaceuticals, Rigel Pharmaceuticals Inc., Retrophin, Omeros
Download the sample report @ https://www.pharmaproff.com/request-sample/1211
IgA Nephropathy is referred to being as the utmost causing agent of Glomerulonephritis, which is the inflammation of the glomeruli (part of the kidney that filters blood). IgA antibodies are produced by immune system and act as first line of defense against inhaled and ingested pathogens. IgA Nephropathy is an auto immune disorder caused due to the accumulation of the immunoglobulin A (IgA) which results in inflammation and further damages the glomeruli in kidney. This damage to kidney results in presence of blood and protein in urine, and over time may progress to end-stage renal disease (ESRD).
Get the detailed analysis @ https://www.pharmaproff.com/report/iga-nephropathy-pipeline-analysis
According to research findings, majority of the drug candidates in IgA Nephropathy pipeline are undergoing Phase II trials and have shown positive results. It has been observed that subcutaneous route of administration is convenient because of more efficacy and safety; it is more adoptable because of its larger dosage, that can be transmitted subcutaneously; sustainable release of drugs is possible as the muscles can slowly release the drugs into the body. Also, according to the analysis, maximum number of drugs in the pipeline are being developed as small molecules.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1211
The epidemiology analysis in the report provides risk factors and trends of IgA Nephropathy in seven major markets (7MM, including U.S., Japan, and EU5 [which includes Germany, France, U.K., Italy, and Spain]) and gives a ten-year forecast for the prevalent and treated cases of IgA nephropathy in each of the regions in pediatric, adult, and geriatric populations. Europe is likely to have the highest number of prevalent cases of IgA Nephropathy among the 7MM throughout the period of analysis.
Some of the key players involved in the development of the drug candidates for IgA Nephropathy in the late and mid stage include Mallinckrodt plc, Calliditas Therapeutics AB., Anthera Pharmaceuticals Inc., Rigel Pharmaceuticals Inc., Merck KGaA, Retrophin Inc., and Omeros Corporation.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immunoglobulin A (IgA) Nephropathy to Witness an Exponential Growth due to Positive Clinical Results in the Coming Years | Key Players are Mallinckrodt Pharmaceuticals, Pharmalink AB, Anthera Pharmaceuticals, Rigel Pharmaceuticals Inc., Retrophin, Omeros here
News-ID: 1674880 • Views: …
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for IgA
IgA Nephropathy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, IgA Nephropathy pipeline constitutes 25+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"IgA Nephropathy Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market.
The IgA Nephropathy Pipeline report…
Multiplier Strengthens Identity Governance with Advanced IGA Solutions
Image: https://www.abnewswire.com/upload/2025/08/8c79c8224ecce453d70ad648fa16d5e9.jpg
Introduction
In today's rapidly evolving digital landscape, managing user identities and access rights has become a critical concern for businesses of all sizes. As organizations expand, ensuring the right individuals have the correct access to systems and data is essential for operational efficiency and security. Multiplier, a leader in innovative enterprise solutions, is empowering companies with comprehensive Identity Governance and Administration (IGA) solutions to address these challenges.
IGA Solutions: The Heart…
IgA Nephropathy Market Positioned for Accelerated Development Through 2032, Delv …
The Key IgA Nephropathy Companies in the market include - Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgA Nephropathy,…
IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Pred …
The Key IgA Nephropathy Companies in the market include - Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgA Nephropathy,…
IgA Nephropathy Drugs Market Trends And Forecast 2023-2030
Innovations and Growth Propel IgA Nephropathy Drugs Market:
Global IgA Nephropathy Drugs Market Expands with Technological Advancements and Research Initiatives
The IgA nephropathy drugs market is witnessing a surge in product launches driven by advancements in technology and an upswing in research and development activities. IgA nephropathy, an autoimmune disease affecting the kidneys, results in inflammation and kidney damage due to the accumulation of antibody clumps. The market is experiencing notable growth,…
IgA Nephropathy Drugs Market Sales, Demands and Forecasts
The IgA Nephropathy Drugs market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with…
